Proteomic profiling to predict therapeutic response to anti-PD1 therapy in advanced melanoma – Orbitrap Elite dataset depleted serum

MS-based proteomics based on data-dependent acquisition / shotgun MS was used to study the response of melanoma patients to anti-PD1 therapy. Human serum samples were collected from patients at the start of their therapy and later categorized into responders and non-responders based on clinical outcome. Samples were subjected to immunodepletion and proteins were identified by bottom-up proteomics.